104 related articles for article (PubMed ID: 11410111)
21. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
22. Beneficial effects of designed dietary fatty acid compositions on lipids in triacylglycerol-rich lipoproteins among Chinese patients with type 2 diabetes mellitus.
Dai J; Su YX; Bartell S; Le NA; Ling WH; Liang YQ; Gao L; Wu HY; Veledar E; Vaccarino V
Metabolism; 2009 Apr; 58(4):510-8. PubMed ID: 19303972
[TBL] [Abstract][Full Text] [Related]
23. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
[TBL] [Abstract][Full Text] [Related]
24. Treatment with insulin glargine does not suppress serum IGF-1.
Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
[TBL] [Abstract][Full Text] [Related]
25. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
[TBL] [Abstract][Full Text] [Related]
26. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokines in insulin-treated patients with type 2 diabetes.
Mavridis G; Souliou E; Diza E; Symeonidis G; Pastore F; Vassiliou AM; Karamitsos D
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):471-6. PubMed ID: 17976964
[TBL] [Abstract][Full Text] [Related]
28. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
29. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
Koga H; Sugiyama S; Kugiyama K; Fukushima H; Watanabe K; Sakamoto T; Yoshimura M; Jinnouchi H; Ogawa H
Eur Heart J; 2006 Apr; 27(7):817-23. PubMed ID: 16434416
[TBL] [Abstract][Full Text] [Related]
30. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Takebayashi K; Suetsugu M; Wakabayashi S; Aso Y; Inukai T
Metabolism; 2007 Apr; 56(4):451-8. PubMed ID: 17378999
[TBL] [Abstract][Full Text] [Related]
31. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
32. Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents.
Hanyu O; Miida T; Kosuge K; Ito T; Soda S; Hirayama S; Wardaningsih E; Fueki Y; Obayashi K; Aizawa Y
Clin Chim Acta; 2007 Sep; 384(1-2):118-23. PubMed ID: 17651713
[TBL] [Abstract][Full Text] [Related]
33. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus.
Ferderbar S; Pereira EC; Apolinário E; Bertolami MC; Faludi A; Monte O; Calliari LE; Sales JE; Gagliardi AR; Xavier HT; Abdalla DS
Diabetes Metab Res Rev; 2007 Jan; 23(1):35-42. PubMed ID: 16634125
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of apolipoprotein E secretion by macrophages in type 2 diabetic patients: role of HDL and apolipoprotein A-I.
Yamato K; Tamasawa N; Murakami H; Matsui J; Tanabe J; Suda T; Yasujima M
Diabetes Res Clin Pract; 2005 Aug; 69(2):124-8. PubMed ID: 16005361
[TBL] [Abstract][Full Text] [Related]
36. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
37. Pseudocholinesterase activity in human cerebrospinal fluid.
Kambam JR; Horton B; Parris WC; Hyman SA; Berman ML; Sastry BV
Anesth Analg; 1989 Apr; 68(4):486-8. PubMed ID: 2929981
[TBL] [Abstract][Full Text] [Related]
38. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Nagai T; Tomizawa T; Nakajima K; Mori M
J Atheroscler Thromb; 2000; 7(2):91-6. PubMed ID: 11426588
[TBL] [Abstract][Full Text] [Related]
39. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Inoue I; Takahashi K; Katayama S; Akabane S; Negishi K; Suzuki M; Ishii J; Kawazu S
Diabetes Res Clin Pract; 1994 Oct; 25(3):199-205. PubMed ID: 7851275
[TBL] [Abstract][Full Text] [Related]
40. Serum pseudocholinesterase and very-low-density lipoprotein metabolism.
Kutty KM; Payne RH
J Clin Lab Anal; 1994; 8(4):247-50. PubMed ID: 7931819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
